Docusate

Summary

Docusate (CHEMBL1477036) is an approved small molecule; indicated across 2 conditions including gastroparesis and constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 422.6 Da · C20H38O7S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1477036
Name	Docusate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	11339
Molecular formula	C20H38O7S
Molecular weight	422.6
InChIKey	HNSDLXPSAYFUHK-UHFFFAOYSA-N

SMILES: CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O

IUPAC name: 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonic acid

Also known as: Diocto, Docusate, Docusates, Spolion 8, SID29216456, SID104171408, DOCUSATE, SID225144252

Parent form; salt/anhydrous children: CHEMBL1905872, CHEMBL2106608, CHEMBL2107648

Patent coverage: 2,828 distinct patent families (5,778 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: ATP-dependent DNA helicase Q1, Ferritin light chain.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastroparesis	2	MONDO:0006769	EFO:1000948
constipation disorder	2	MONDO:0002203	HP:0002019

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	2
Not specified	2
PHASE4	1
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00799201	PHASE4	TERMINATED	Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients
NCT00571896	PHASE2/PHASE3	COMPLETED	The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery
NCT01474499	PHASE3	COMPLETED	A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
NCT00001337	PHASE2	COMPLETED	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
NCT03342157	PHASE2	TERMINATED	Docusate/Senna for the Treatment of Diabetic Gastroparesis
NCT00902031	Not specified	COMPLETED	Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients
NCT01044212	Not specified	COMPLETED	Bowel Function After Minimally Invasive Urogynecologic Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).